Safe Harbor Statement

This presentation contains forward-looking statements that involve risks and uncertainties, including risks associated with the regulatory approval process for new drug products, clinical development, commercialization, company financing and other risks described from time to time in SEC reports filed by Amylin Pharmaceuticals, Inc. including the most recent 10-K and 10-Qs, and recently filed S-3.

Improving the Lives of People with Metabolic Diseases

Previous slide

Next slide

Back to first slide

View graphic version